Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director Dealings

20th May 2016 10:16

RNS Number : 8612Y
Sinclair Pharma PLC
20 May 2016
 

 

Sinclair Pharma plc

 

Director dealings

 

20 May 2016, Sinclair Pharma plc (SPH.L) ("Sinclair" or the "Company") the international aesthetics company, has been advised that Julie Spooner, wife of Chris Spooner, Chief Executive Officer, has acquired today 150,000 ordinary shares of 1p each ("Ordinary Shares") in the Company at 35.4p per Ordinary Share. In addition, Christophe Foucher, Chief Operating Officer, has acquired today a further 31,500 Ordinary Shares in the Company at 35.5p per Ordinary Share.

 

Following these purchases, Chris Spooner's total beneficial interest is 9,139,164 Ordinary Shares, 1.84%, and Christophe Foucher is interested in 222,700 Ordinary Shares, 0.04% of the issued share capital of the Company.

 

 

For further information please contact:

 

Sinclair Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Andy Crane

 

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

 

 

Notes to Editors:

 

About Sinclair Pharma plc 

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors.

 

For more information, please visit www.sinclairpharma.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGCGDUXBDBGLG

Related Shares:

Sinclair Pharma
FTSE 100 Latest
Value8,809.74
Change53.53